NR1I2 and non-small cell lung carcinoma: Overall, the above evidence proved that a combined regimen of the PXR antagonist SPA70 with PTX had a stronger inhibitory effect on PTX-resistant tumor growth than single compound treatment, indicating SPA70 might be a potent candidate to overcome PTX resistance in NSCLC cells.